Han Shih Toh

With the HKMA close to issuing licences, yuan-linked stablecoins could help boost the internationalisation of the Chinese currency.

Amid a structural shift towards Asia, Insilico Medicine's IPO in December was a significant moment for the exchange, while French biotech TheraVectys is understood to be considering a listing.

The Chinese property giant's debt woes will not seriously affect China’s property sector, according to analysts; however, a restructuring might be on the cards.

China’s new five-year plan for 2026–2030 marks a decisive policy shift, placing domestic consumption and reform at the core of its growth strategy.

Beijing is encouraging A-share listed firms to list in Hong Kong, while Trump’s policies are turning some US-listed Chinese companies to also go public on HKEX. The IPO momentum is continuing with four firms listing on October 28 in the SAR.

Hong Kong-listed biotech firms are outperforming as Trump’s policies cause firms to change course from their traditional US destination, with more HKEX listings expected in the second half of 2025; experts shared their views at BIOHK.

In the long run, as China’s currency is increasingly used abroad, it will be one of the few leading global currencies, however US strength will maintain the supremacy of the US dollar, according to analysts at a Sino-German roundtable.

Chinese overseas investments, including in emerging markets, should boost the domestic economy; meanwhile, US president Donald Trump and China have extended a ‘tariff truce’ until November 10.

With geopolitical tensions rising, Beijing’s new Hong Kong–Shenzhen policy aims to open alternative capital channels

Asia's listed firms must raise their corporate governance to improve market conditions, as international investors continue to eye the US stock market, the Asian Corporate Governance Association has warned.